Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 EUR | +0.10% | -8.68% | +26.18% |
May. 30 | Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 30 | Transcript : Nanoform Finland Oyj, Q1 2024 Earnings Call, May 30, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
145.4 USD | -1.84% | -3.85% | 16.18B | ||
2 EUR | +0.10% | -8.68% | 186M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.18% | 186M | |
+45.37% | 56.65B | |
-7.33% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.30% | 26.75B | |
-21.47% | 19.03B | |
+0.69% | 12.28B | |
+24.02% | 12.26B | |
+27.17% | 12.04B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants